The Role of High-Dose IL-2 in RCC
Mario Sznol, MD, professor of medicine, Yale Cancer Center, discusses the role of high-dose IL-2 for the treatment of renal cell carcinoma (RCC).
Clinical Pearls
Mario Sznol, MD, professor of medicine, Yale Cancer Center, discusses the role of high-dose IL-2 for the treatment of renal cell carcinoma (RCC).
- There is still a role for high-dose IL-2 in RCC.
- Anti-PD-1 agents are active, but a different population of patients may respond to high-dose IL-2.
- Both agents are necessary to achieve durable remissions.
- If combinations with anti-PD-1 agents prove to be active, IL-2 may be moved to the second- or third-line.
Peers Discuss Management of IO/TKI Toxicities and Dosing Strategies in Frontline RCC
March 11th 2025During a Case-Based Roundtable® event, Elizabeth M. Wulff-Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal cell carcinoma.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
